Print

Purpose

The objective of this study is to evaluate the safety and efficacy of up to 26 weeks of treatment with calcitriol 3 mcg/g ointment when used twice daily, without occlusion, to treat pediatric subjects (2 to 16 years and 11 months of age) with mild to moderate plaque psoriasis.

Condition

Eligibility

Eligible Ages
Between 2 Years and 16 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Male or female 2 to 16 years and 11 months of age - Clinical diagnosis of stable mild to moderate plaque psoriasis

Exclusion Criteria

  • Other forms of psoriasis - Hypercalcemia - Past history of kidney stones - Vitamin D deficiency - Other concomitant dermatological disease

Study Design

Phase
Phase 4
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Calcitriol ointment
  • Drug: Calcitriol

More Details

Status
Completed
Sponsor
Galderma R&D

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.